Roger Paredes, MD, PhD
Roger Paredes, MD, PhD
Infectious Diseases Service & irsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias
Verified email at irsicaixa.es
Title
Cited by
Cited by
Year
2011 update of the drug resistance mutations in HIV-1
VA Johnson, V Calvez, HF Günthard, R Paredes, D Pillay, R Shafer, ...
Topics in antiviral medicine 19 (4), 156, 2011
11662011
2015 update of the drug resistance mutations in HIV-1
AM Wensing, V Calvez, HF Günthard, VA Johnson, R Paredes, D Pillay, ...
Top Antivir Med 23 (4), 132-41, 2015
6262015
Special contribution 2014 Update of the drug resistance mutations in HIV-1
AM Wensing, V Calvez, HF Günthard, VA Johnson, R Paredes, D Pillay, ...
Topics in antiviral medicine 22 (3), 642, 2014
626*2014
Special contribution 2014 Update of the drug resistance mutations in HIV-1
AM Wensing, V Calvez, HF Günthard, VA Johnson, R Paredes, D Pillay, ...
Topics in antiviral medicine 22 (3), 642, 2014
626*2014
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects
MJ Buzón, M Massanella, JM Llibre, A Esteve, V Dahl, MC Puertas, ...
Nature medicine 16 (4), 460, 2010
5582010
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a …
L Wittkop, HF Günthard, F De Wolf, D Dunn, A Cozzi-Lepri, A De Luca, ...
The Lancet infectious diseases 11 (5), 363-371, 2011
3682011
Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis
JZ Li, R Paredes, HJ Ribaudo, ES Svarovskaia, KJ Metzner, MJ Kozal, ...
Jama 305 (13), 1327-1335, 2011
3372011
Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy.
A Tuldrà, CR Fumaz, MJ Ferrer, R Bayés, A Arnó, M Balagué, A Bonjoch, ...
Journal of acquired immune deficiency syndromes (1999) 25 (3), 221-228, 2000
3172000
Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population
AJ Rodger, R Lodwick, M Schechter, S Deeks, J Amin, R Gilson, ...
Aids 27 (6), 973-979, 2013
3072013
Update of the drug resistance mutations in HIV-1: March 2013
VA Johnson, V Calvez, HF Günthard, R Paredes, D Pillay, RW Shafer, ...
Topics in antiviral medicine 21 (1), 6, 2013
3002013
Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study
R Paredes, A Mocroft, O Kirk, A Lazzarin, SE Barton, J Van Lunzen, ...
Archives of internal medicine 160 (8), 1123-1132, 2000
2842000
Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo
AMN Tsibris, B Korber, R Arnaout, C Russ, CC Lo, T Leitner, B Gaschen, ...
PloS one 4 (5), 2009
2332009
Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression
L Ruiz, J Martinez-Picado, J Romeu, R Paredes, MK Zayat, S Marfil, ...
Aids 14 (4), 397-403, 2000
2302000
Barriers to reducing urinary catheter use: a qualitative assessment of a statewide initiative
SL Krein, CP Kowalski, M Harrod, J Forman, S Saint
JAMA internal medicine 173 (10), 881-886, 2013
228*2013
Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure
R Paredes, CM Lalama, HJ Ribaudo, BR Schackman, C Shikuma, ...
The Journal of infectious diseases 201 (5), 662-671, 2010
2122010
Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and …
E Negredo, L Cruz, R Paredes, L Ruiz, CR Fumaz, A Bonjoch, S Gel, ...
Clinical infectious diseases 34 (4), 504-510, 2002
2082002
Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a …
L Ruiz, E Negredo, P Domingo, R Paredes, E Francia, M Balagué, S Gel, ...
Journal of acquired immune deficiency syndromes (1999) 27 (3), 229-236, 2001
2032001
Gut microbiota linked to sexual preference and HIV infection
M Noguera-Julian, M Rocafort, Y Guillén, J Rivera, M Casadellà, P Nowak, ...
EBioMedicine 5, 135-146, 2016
1822016
Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens
CR Fumaz, A Tuldra, MJ Ferrer, R Paredes, A Bonjoch, T Jou, E Negredo, ...
JAIDS-HAGERSTOWN MD- 29 (3), 244-253, 2002
1792002
HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection
L Ruiz, G Carcelain, J Martínez-Picado, S Frost, S Marfil, R Paredes, ...
Aids 15 (9), F19-F27, 2001
1772001
The system can't perform the operation now. Try again later.
Articles 1–20